Dendritic-cell-based therapeutic vaccination against cancer.

Détails

ID Serval
serval:BIB_1356634020D0
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Dendritic-cell-based therapeutic vaccination against cancer.
Périodique
Current Opinion in Immunology
Auteur(s)
Nestle F.O., Farkas A., Conrad C.
ISSN
0952-7915 (Print)
ISSN-L
0952-7915
Statut éditorial
Publié
Date de publication
2005
Volume
17
Numéro
2
Pages
163-169
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't ; Review
Résumé
Early clinical trials, in which over 1000 cancer patients received dendritic cell (DC) vaccines, tested different vaccine preparations, but they did not always induce sufficient acquired immunity or meet the expected level of tumor regressions. Current studies aim to improve the DC vaccine approach and capture the potential of these cells in order to gain access to lymphoid tissues and induce strong cell-mediated immunity. DC clinical trials are moving towards a more professional environment, in accordance with the latest quality standards. This explains the current need for innovative well designed trials with defined endpoints that induce robust anti-tumor immunity.
Mots-clé
Animals, Antigens/immunology, Antigens/therapeutic use, Cancer Vaccines/administration & dosage, Cancer Vaccines/immunology, Dendritic Cells/immunology, Humans, Injections, Intralymphatic, Neoplasms/drug therapy, Neoplasms/immunology
Pubmed
Web of science
Création de la notice
26/03/2012 11:36
Dernière modification de la notice
20/08/2019 13:41
Données d'usage